Cefobid Side Effects
Generic name: cefoperazone
Note: This document contains side effect information about cefoperazone. Some of the dosage forms listed on this page may not apply to the brand name Cefobid.
Some side effects of Cefobid may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
Applies to cefoperazone: injectable powder for injection
A case of occupational contact dermatitis due to cephalosporin allergy has been reported in a nurse who prepared cephalosporin solutions for administration to patients. The dermatitis resolved after the nurse stopped preparing the solutions.
Hypersensitivity reactions, often manifested as skin rashes, are common with cefoperazone and may require drug discontinuation. Drug fever and changes in Coombs' tests have also been reported. Allergic cross-reactivity may occur in patients allergic to penicillin. Cephalosporin class antibiotics have been associated with anaphylaxis, Stevens-Johnson syndrome, erythema multiforme, and toxic epidermal necrolysis.
The frequent occurrence of diarrhea is thought to be due to the disturbance of intestinal flora from high biliary concentrations of cefoperazone (the active ingredient contained in Cefobid) In a study evaluating the intestinal side effects of cefoperazone, Clostridium difficile was found in the stool of several patients with diarrhea. In at least three of these cases no treatment was necessary and symptoms resolved.
Gastrointestinal side effects have included nausea, vomiting and diarrhea, the latter being the most frequent. Clostridium difficile has been documented in some patients receiving cefoperazone.
Hepatic side effects have included alterations in serum transaminases and alkaline phosphatase in 5% to 10% of patients, but drug discontinuation was usually not necessary. These changes are usually mild and transient and return to normal following completion of therapy. Cephalosporins as a class have been associated with hepatic dysfunction including cholestasis.
The effect of cefoperazone (the active ingredient contained in Cefobid) on hemostasis has been evaluated in at least one study and reported in several cases. In most of these cases, the patient had normal coagulation parameters, prothrombin time and partial thromboplastin time prior to starting cefoperazone therapy. Within several days to weeks, prolongation of prothrombin time and partial thromboplastin time developed. Bleeding occurred in some cases. Administration of vitamin K or fresh frozen plasma corrected the changes in most of these patients. Cefoperazone was continued in several patients.
Hematologic abnormalities have included eosinophilia, neutropenia, decreases in hemoglobin and hematocrit, thrombocytopenia, hypoprothrombinemia, and leukopenia. In most cases, these alterations do not require drug discontinuation or dosage reduction. Cephalosporins as a class have been associated with aplastic anemia, hemolytic anemia, prolonged prothrombin time, hemorrhage, neutropenia, pancytopenia, and agranulocytosis.
Renal side effects have included transient elevations of BUN and creatinine, and acute interstitial nephritis with renal failure. Cephalosporins as a class have been associated with renal dysfunction and toxic nephropathy.
Local side effects have included pain after intramuscular injection and phlebitis after intravenous infusion.
Dermatologic side effects associated with cephalosporin class antibiotics have included rash, Stevens-Johnson syndrome, erythema multiforme, and toxic epidermal necrolysis.
Nervous system side effects associated with some cephalosporins have included seizures in renally impaired patients.
More Cefobid resources
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.